Orexo AB (ORX) Jumps 0.13% on Apr 12

Shares of Orexo AB (STO:publ) last traded at 75, representing a move of 0.13%, or 0.1 per share, on volume of 192,651 shares. After opening the trading day at 74.9, shares of Orexo AB traded in a close range. Orexo AB currently has a total float of 34.60 million shares and on average sees 168,289 shares exchange hands each day. The stock now has a 52-week low of 28.1 and high of 87.9.

Nasdaq Stockholm: A Nordic Nation’s Pride

Sweden is home to one of the best and most accomplished economies in the world. It is truly a pride of the European Union (EU), especially now that Great Britain has decided to leave the political organization. Orexo AB is not very concern for its investors. With the Brexit, the Swedish economy is now more than ever at a more competent position to carry out growth prospects.

Stockholm Stock Exchange or Nasdaq Stockholm

The Nasdaq Stockholm, located in Frihamnen, Stockholm, is the primary stock exchange in Sweden. It is also one of the main stock exchanges in other Nordic countries including Denmark, Finland, Iceland, and Norway.

The Nasdaq Stockholm had been established as early as 1863, making it one of the oldest stock exchange in Europe and in the world as well. Until about the first half of the calendar year 1990, trading on the Nasdaq Stockholm occurs on the floor at the Stockholm Stock Exchange Building. Electronic trading was only launched on June 1, 1990. And now it provides numerous improvements in the common work for Orexo AB.

Nasdaq, Inc. owns the Nasdaq Stockholm since 2008. Consequently, it is part of Nasdaq Nordic, a subsidiary of Nasdaq founded in 2003. Other stock exchanges overseen by Nasdaq Nordic include the Armenia Stock Exchange or Nasdaq OMX Armenia, the Copenhagen Stock Exchange or Nasdaq Copenhagen, the Helsinki Stock Exchange or Nasdaq Helsinki, the Iceland Stock Exchange or Nasdaq Iceland, the Riga Stock Exchange or Nasdaq Baltic, and the Tallinn Stock Exchange or Nasdaq Baltic.

As of March, more than 300 companies are listed on the Nasdaq Stockholm. In totality, it has a market capitalization of roughly $1.26 trillion.

The regular trading session on the Nasdaq Stockholm begins at 9:00 a.m. and ends at 5:00 p.m.

OMX Stockholm 30 Index (OMXS30)

The OMXS30 is the benchmark Swedish index measuring the top 30 stocks on the Nasdaq Stockholm based on market capitalization. It uses the base value of 125 points, which has a base date of September 1986. The OMXS30 has numerous sectors; and the three biggest sectors include Consumer Services, Financials, and Industrials. OMXS30 guarantee the stability for Orexo AB work, as well.

The components of the OMXS30 are reviewed semi-annually in order to guarantee an accurate representation of the Swedish equity market. During rebalancing periods, it is only normal for the OMXS30 to forego some components and welcome new ones. It always depends on the companies’ liquidity, market capitalization, and several other factors.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

The OMXS30 has touched its all-time low of 98.86 points in November 1987. The substantial losses are widely attributed to the Black Monday, an occurrence that had shaken the global equity market. It all began when stocks on the Stock Exchange of Hong Kong (SEHK) had significantly declined on October 19, 1987.

Eventually, the OMXS30 was able to recoup from the dark times in global economy history. It has touched its all-time high of 1,719.93 in April 2015.

Today is the best time to enter the European equity market, particularly that of Sweden. And perhaps check some companies like Orexo AB. With low interest rates, Europe is surely an ideal place for investors to bet on through the Nasdaq Stockholm.

More notable recent Orexo AB (STO:publ) news were published by: Businesswire.com which released: “Orexo: Favorable outcome from Zubsolv® patent infringement litigation against Actavis – Business Wire” on November 16, 2016, also Globenewswire.com with their article: “FDA approves the medium tablet strength, 2.9 mg/0.71 mg, of ZUBSOLV® – GlobeNewswire” published on June 10, 2015, Businesswire.com published: “Orexo Settles Abstral® US Patent Litigation with Actavis – Business Wire” on October 27, 2015. More interesting news about Orexo AB (STO:publ) were released by: Businesswire.com and their article: “Number of Shares and Votes in Orexo – Business Wire” published on January 30, 2015 as well as Businesswire.com‘s news article titled: “Orexo: U.S. FDA Approves ZUBSOLV® for Induction of Buprenorphine Maintenance Therapy in Patients Suffering from Opioid Dependence – Business Wire” with publication date: August 11, 2015.

Orexo AB , a specialty pharmaceutical company, engages in the development and commercialization of drugs. The company has market cap of $2.60 billion. The Company’s products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, an active substance zolpidem that is used for the treatment of short-term insomnia. It has a 19.08 P/E ratio. The company's development projects comprise OX382, oral formulation of buprenorphine; OX-CLI, a novel treatment of respiratory disorders, such as asthma and COPD; OX-MPI, for inflammatory related pain; and OX51, a sublingual formulation containing alfentanil for the prevention of acute pain during short surgical and diagnostic procedures.